Medicines in Development

Molecule & Potential Indication Data as of July 28, 2020

Interested in Lilly clinical trials? Learn more at

Molecule Group Filters

Therapeutic Areas:


regulatory approval achieved milestone achieved new to pipeline

Regulatory Approval Achieved

view portfolio

Regulatory Review

view portfolio

Phase 3

view portfolio

Pipeline Disclaimer

The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 28, 2020. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.

Property of Eli Lilly and Company.

Frequently Asked Questions

Thank you for visiting Lilly’s clinical development pipeline site. This interactive page is designed to give you a better understanding of the molecules and potential indications Lilly is currently developing for people around the world. Below are responses to some frequently asked questions regarding the site’s information and how it is displayed.